Quilostigmine

Drug Profile

Quilostigmine

Alternative Names: NXX 066

Latest Information Update: 20 Oct 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Indoles; Isoquinolines; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 28 Sep 2001 No-Development-Reported for Alzheimer's disease in Sweden (Unknown route)
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
  • 01 Jul 1998 A study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top